drugset / Trial / NCT07038915
STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1
NaSingle-groupOpen-labelTreatment
Summary
To learn if the drug combination of tiragolumab and ivonescimab can help to control LSCC that got worse after standard treatment with platinum doublets and anti-PD-1/PD-L1 therapy.
Timeline
- Start
- 2025-07-28
- Primary completion
- 2025-07-28
- Completion
- 2025-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | — | Other |
| Subject | Tiragolumab | Monoclonal antibody | — | Other |